A blood test may help detect cancer

Precise News

A blood test appears capable of detecting early-stage pancreatic cancers with up to 97% accuracy, a new study reports.
An earlier trial of this blood test in 95 patients from the U.S. and Japan found a detection rate of 98%.
Advertisement The blood test detected: 93% of pancreatic cancers among the U.S. participants.
91% of pancreatic cancers among the South Koreans.
88% of pancreatic cancers in the Chinese group.
When researchers combined the blood test with a test for an already-established pancreatic cancer marker called CA 19-9, the accuracy increased to 97% of stage 1 and 2 cancers among the U.S. participants.
Stage 1 pancreatic cancers are confined to the organ, while stage 2 have spread to nearby lymph nodes but not elsewhere.
More information The American Cancer Society has more on pancreatic cancer.


According to a new study, there seems to be a 97 percent accuracy rate in blood testing for the detection of early-stage pancreatic cancer.

In order to identify a genetic “signature” for pancreatic cancer, the test searches for eight distinct types of DNA markers and eight smaller RNA particles that are released by the disease, according to researchers.

It is currently difficult to detect pancreatic cancer in its advanced stages. The cancer has symptoms that are mistakenly mistaken for other illnesses, and the organ is deep within the abdomen.

In a news release, senior researcher Ajay Goel, chair of molecular diagnostics and experimental therapeutics at City of Hope Cancer Center, stated that pancreatic cancer is one of the most deadly cancers, “largely because most patients are diagnosed only after the cancer has already metastasized.”.

Researchers found that although the five-year survival rate for patients with early-stage pancreatic cancer is 44%, it falls to 3% if the cancer is discovered after it has spread to other parts of the body.

95 patients from the U.S. participated in an earlier trial of this blood test. S. 98 percent of cases were detected in Japan.

461 healthy participants from Japan and the U.S. participated in this most recent trial along with 523 pancreatic cancer patients. S. China, Korea South.

What the blood test found was:.

A staggering 93% of pancreatic cancer cases in the U.S. S. participants.

South Koreans account for 91% of pancreatic cancer cases.

The Chinese group had 88% of the pancreatic cancers.

When researchers paired the blood test with an existing pancreatic cancer marker test, known as CA 19-9, the test’s accuracy rose to 97 percent of stage 1 and stage 2 cancers among U.S. s. participants.

While stage 2 pancreatic cancers have spread to neighboring lymph nodes but not outside of the organ, stage 1 cancers are limited to the organ itself.

In comparison to CA19-9 measurement alone, Goel stated, “our approach offers a liquid biopsy test superior to early-stage disease.”.

Before the test is made available to the general public, more research is necessary to validate it, according to the researchers.

On Monday, at a meeting of the American Association for Cancer Research in San Diego, researchers were supposed to present the trial results. Results that are presented at conferences for medical professionals should be regarded as preliminary until they are published in a peer-reviewed publication.

More information.

For more information on pancreatic cancer, visit the American Cancer Society.

2024 HealthDay Copyright ©. All rights reserved.

scroll to top